NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.9
41.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| NL |
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
3.8B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.4B USD |
Loading...
|
Market Distribution
| Min | -54 745% |
| 30th Percentile | 1.6% |
| Median | 8.1% |
| 70th Percentile | 13.6% |
| Max | 288.5% |
Other Profitability Ratios
NewAmsterdam Pharma Company NV
Glance View
NewAmsterdam Pharma Company NV is forging its path in the biotech industry with a focus on developing transformative therapies aimed at combating cardiovascular diseases. Emerging from the innovative medical landscape in the Netherlands, the company's keystone is its investigational drug obicetrapib, designed to address the pervasive issue of cardiovascular conditions by significantly lowering LDL cholesterol levels. Through its strategic partnerships and rigorous clinical trials, NewAmsterdam Pharma is committing substantial resources to redefining treatment options for this worldwide health threat. By zeroing in on cholesterol reduction, the company aims to meet an unrelenting demand within the healthcare sector for more effective and accessible cholesterol management solutions. The company’s business model revolves around the commercialization of its proprietary drugs while leveraging collaborations with major pharmaceutical entities to expand its pipeline and market reach. By investing heavily in research and development, NewAmsterdam Pharma believes that it can not only improve global health outcomes but also establish a sustainable revenue stream through the licensing of its compounds and successful drug launches. Capitalizing on both private investments and strategic alliances, the company makes money by bringing its innovations from the lab to the market, thus addressing a critical medical need with the potential to reduce healthcare costs associated with long-term cardiovascular care. Through diligence and determination, NewAmsterdam Pharma is poised to potentially change the landscape of cardiovascular therapy, converting scientific breakthroughs into lifelines for patients worldwide.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for NewAmsterdam Pharma Company NV is -116.7%, which is below its 3-year median of -64.8%.
Over the last 6 months, NewAmsterdam Pharma Company NV’s Operating Margin has decreased from -3.8% to -116.7%. During this period, it reached a low of -125.7% on Jul 30, 2023 and a high of -3.8% on Dec 31, 2022.